---
title: Daratumumab or Active Monitoring for High-Risk Smoldering Multiple Myeloma
date: '2024-12-09'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/39652675/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20241209184155&v=2.18.0.post9+e462414
source: heidelberg[Affiliation]
description: 'CONCLUSIONS: Among patients with high-risk smoldering multiple myeloma,
  subcutaneous daratumumab monotherapy was associated with a significantly lower risk
  of progression to active multiple myeloma or death and with higher overall survival
  than active monitoring. No unexpected safety concerns were identified. (Funded by
  Janssen Research and Development; AQUILA ClinicalTrials.gov number, ...'
disable_comments: true
---
CONCLUSIONS: Among patients with high-risk smoldering multiple myeloma, subcutaneous daratumumab monotherapy was associated with a significantly lower risk of progression to active multiple myeloma or death and with higher overall survival than active monitoring. No unexpected safety concerns were identified. (Funded by Janssen Research and Development; AQUILA ClinicalTrials.gov number, ...